Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
McDiarmid S et al. | One hundred children treated with tacrolimus after primary orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636564 |
Wiesner RH | Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. | 1998 | Transplant. Proc. | pmid:9636565 |
Van Buren D et al. | Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). | 1998 | Transplant. Proc. | pmid:9636566 |
Jain A et al. | Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. | 1998 | Transplant. Proc. | pmid:9636567 |
Zervos XA et al. | Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636568 |
Millis JM et al. | Successful use of tacrolimus for initial rejection episodes after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636569 |
Platz KP et al. | FK506 for primary and rescue therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636570 |
Taibi A et al. | Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. | 1998 | Transplant. Proc. | pmid:9636571 |
Cai TH et al. | Improved immunosuppression with combination tacrolimus (FK506) and mycophenolic acid in orthotopic liver transplantation. | 1998 | Transplant. Proc. | pmid:9636572 |
Ringe B et al. | Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. | 1998 | Transplant. Proc. | pmid:9636573 |
Rudich SM et al. | Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. | 1998 | Transplant. Proc. | pmid:9636574 |
Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results. | 1998 | Transplant. Proc. | pmid:9636575 |
Bilbao I et al. | Experience with neoral cyclosporine through the oral route in liver transplantation. | 1998 | Transplant. Proc. | pmid:9636580 |
Langrehr JM et al. | Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636583 |
Abe M et al. | Successful prednisone withdrawal after living-related liver transplantation. | 1998 | Transplant. Proc. | pmid:9636584 |
Klupp J et al. | Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. | 1998 | Transplant. Proc. | pmid:9636585 |
Steinmueller T et al. | Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. | 1998 | Transplant. Proc. | pmid:9636589 |
Liu WT et al. | In vitro generation of tacrolimus metabolites and their detection in whole blood. | 1998 | Transplant. Proc. | pmid:9636590 |
Bekersky I et al. | Bioequivalence of a new strength tacrolimus capsule under development. | 1998 | Transplant. Proc. | pmid:9636591 |
Cantarovich M et al. | Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. | 1998 | Transplant. Proc. | pmid:9636592 |